Scientists at the Hudson Institute of Medical Research have made a groundbreaking discovery that could revolutionize our understanding of stomach cancer and peptic ulcers. Led by Jack Emery and Professor Richard Ferrero, the team has uncovered a novel mechanism by which the bacterium Helicobacter pylori, a global infection with deadly consequences, delivers a key disease-causing protein into human cells. This breakthrough provides a new scientific insight into how H. pylori modulates chronic inflammation and promotes cancer, potentially opening new diagnostic and therapeutic pathways.
The study, published in the Journal of Extracellular Vesicles, reveals that a poorly understood H. pylori virulence factor, Tipα, is not simply secreted into the stomach environment. Instead, it is packaged inside tiny nano-sized particles called extracellular vesicles (EVs), microscopic "delivery pods" that transport bacterial molecules into human cells. This discovery positions Hudson Institute as a global leader in H. pylori biology and provides crucial new insights into how the bacterium contributes to stomach cancer, which remains one of the world's deadliest cancers.
H. pylori infects 43.9% of the global population, and while many people never experience symptoms, the bacterium is responsible for 90% of non-cardia stomach cancers, 92% of MALT lymphomas, and a major proportion of peptic ulcers. Stomach cancer has a five-year survival rate of just 40%, largely because it is often diagnosed late. Understanding how H. pylori manipulates stomach cells is essential if we want to understand and prevent cancer, says Jack Emery. Antibiotics can clear the infection, but once cancer develops, treatment options are limited. We need new tools, and that starts with understanding the biology.
Tipα has been known to scientists for years, but previous studies produced conflicting results about what Tipα actually does. Some research suggested Tipα triggers strong inflammation, while others hinted that Tipα might behave differently depending on the strain. The Hudson team's findings resolve these contradictions by showing that Tipα behaves differently when delivered by extracellular vesicles. This was the missing piece, Jack Emery explains. Tipα's behavior only makes sense once you understand how it is transported into cells.
The team also found that the amounts of Tipα secreted in EVs vary between different H. pylori strains. It remains an open question whether the amount of Tipα that is secreted correlates with cancer risk. Using biochemical analysis, imaging, and cell-based experiments, the researchers uncovered several major findings: Tipα is packaged inside H. pylori extracellular vesicles, EVs are the main mechanism of Tipα secretion, EVs deliver Tipα directly into the nucleus of human stomach cells, and EV-associated Tipα suppresses inflammation.
This overturns earlier studies that claimed Tipα increases inflammation. We found that when Tipα is delivered via EVs, it can actually temper the inflammatory response, Jack says. It reduces production of TNF and IL-8, which may help H. pylori persist in the stomach for decades. This ability to dampen inflammation may create the chronic, low-grade inflammatory environment that eventually leads to stomach cancer.
The discovery provides a new perspective on how H. pylori interacts with host cells to cause disease and may be relevant to other bacterial infections. It is the first time a bacterial virulence factor has been shown to be primarily secreted via extracellular vesicles. It also helps explain how H. pylori can manipulate the immune system without invading host cells.
The team's findings open several promising avenues for prevention and early detection. Tipα-containing EVs may be detectable in blood, saliva, or gastric fluid, offering a potential early warning sign of infection or cancer risk. Understanding how Tipα is packaged and delivered may help researchers design vaccines that block this process. If Tipα helps H. pylori evade the immune system, targeting EV-mediated delivery could weaken the bacterium's ability to persist.
Ultimately, one of our goals is to develop better tools to identify those individuals who are most at risk and prevent cancer before it develops, Dr. Emery says. The research was led by Professor Ferrero's group at Hudson Institute and involved collaborators from UNSW Sydney and international partners in Thailand, Brazil, the United States, and France, reflecting the global importance of H. pylori research. The team is now investigating how Tipα interacts with human DNA, whether Tipα-containing EVs can be detected in patient samples, how EV-mediated delivery influences long-term cancer risk, and whether blocking EV formation could weaken H. pylori infection.
With stomach cancer ranking fifth globally for both incidence and mortality, the need for new prevention strategies is urgent. By revealing how H. pylori uses extracellular vesicles to deliver a key virulence factor into human cells, Hudson researchers have opened the door to a new mechanism by which the bacterium causes disease. This is the kind of fundamental discovery that is essential if we want to develop new diagnostics or treatments and make stomach cancer far more preventable, Professor Ferrero says.
